Exo Debuts New Point-of-Care Ultrasound Modality
The Exo Iris reportedly combines advanced silicon technology with imaging, workflow software and artificial intelligence (AI) to facilitate multidisciplinary use of point-of-care ultrasound.
Emphasizing ease of use, enhanced imaging quality and artificial intelligence features, Exo has launched the Exo Iris point-of-care ultrasound modality.
In addition to acquiring images with a sweep of one’s wrist via patented SweepAI™ technology, the Exo Iris blends silicon technology with piezoelectric crystals to facilitate rapid delivery of image quality, according to Exo.
The company said other features of Exo Iris include the ability of the ultrasound platform to provide multi-organ scans, assess fine structures and offer guidance for IVs and line procedures.
Key AI features include assessment of bladder volume in seconds with Bladder AI and forthcoming real-time guidance and triage capabilities with Cardiac and Lung AI suites that are pending FDA 510(k) clearance, according to Exo.
“Exo Iris delivers an entirely new approach to the design of ultrasound; one that doesn’t look at ultrasound as a device-only purchase, but seamlessly brings together a complete solution that includes imaging, workflow, and real-time AI in one platform,” noted Arun Nagdev, M.D., the senior director of clinical education at Exo.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
